Jatenzo Mechanism of Action: Full Pathway From Capsule to Androgen Receptor

Why Oral Testosterone Failed Before Jatenzo

Every prior attempt at oral testosterone replacement ran into the same pharmacologic wall: the liver destroyed it. Conventional oral testosterone undergoes extensive first-pass hepatic metabolism, leaving almost no bioavailable drug in systemic circulation. The workaround used for decades, 17-alpha-alkylated androgens like methyltestosterone, protected the molecule from hepatic degradation but caused dose-dependent hepatotoxicity, including peliosis hepatis and cholestatic jaundice [1].

The Endocrine Society's 2018 clinical practice guideline explicitly recommended against 17-alpha-alkylated oral androgens, stating they "should not be used for testosterone replacement" due to liver toxicity risk [2]. This left injectable, transdermal, and buccal formulations as the only viable options for years.

Testosterone undecanoate (TU) solved the hepatic problem through chemistry. By esterifying testosterone at the 17-beta hydroxyl position with an 11-carbon undecanoic acid chain, the molecule becomes highly lipophilic [3]. That lipophilicity is what redirects absorption away from the portal circulation and into the lymphatic system. But the raw compound alone was inconsistent. Absorption varied wildly depending on meal fat content and individual lymphatic function. Jatenzo's contribution was engineering a delivery system that made lymphatic uptake reliable enough for clinical use.

The SEDDS Formulation: Engineering Reliable Lymphatic Uptake

Jatenzo's core innovation is its self-emulsifying drug delivery system. This matters.

The SEDDS formulation contains testosterone undecanoate dissolved in a precise mixture of lipids, surfactants, and co-solvents within a soft gelatin capsule. When the capsule dissolves in the stomach and duodenum, these excipients spontaneously form fine lipid emulsion droplets (typically 100 to 250 nm) upon contact with gastrointestinal fluids and bile salts [4]. The emulsion droplets incorporate TU into their lipid core, presenting it to enterocytes in a form optimized for chylomicron assembly.

Enterocytes in the small intestine absorb these lipid-drug particles through both passive diffusion and active lipid transport pathways. Inside the enterocyte, TU partitions into nascent chylomicrons being assembled in the endoplasmic reticulum. These chylomicrons are secreted basolaterally into intestinal lacteals, the blind-ended lymphatic capillaries of the villi, rather than into the mesenteric capillaries feeding the portal vein [3].

This is the key branch point. Drugs entering portal capillaries travel directly to the liver. Drugs entering lacteals travel through mesenteric lymph nodes, the cisterna chyli, and the thoracic duct before emptying into the left subclavian vein [5]. The liver never sees them at first pass.

The FDA label specifies that Jatenzo must be taken with food, and the prescribing information notes that absorption increases approximately 2- to 5-fold when taken with a meal containing at least 30% fat compared to fasting conditions [6]. Fat intake stimulates bile secretion, increases chylomicron production, and enhances lymphatic flow rate, all of which amplify TU absorption.

From Lymphatic Circulation to Free Testosterone

Once chylomicrons carrying TU reach systemic venous blood, two things happen in sequence. First, lipoprotein lipase (LPL) in capillary endothelium throughout the body hydrolyzes the triglyceride core of the chylomicrons, releasing their cargo. TU is liberated into the plasma compartment [3].

Second, nonspecific esterases in plasma, red blood cells, and peripheral tissues cleave the undecanoate ester bond at the C-17 position. This hydrolysis yields free testosterone and undecanoic acid [4]. The undecanoic acid is a naturally occurring medium-chain fatty acid that enters normal beta-oxidation. Nothing about it is pharmacologically novel or concerning.

The result is bioidentical testosterone circulating in blood. It is chemically indistinguishable from endogenously produced testosterone. Approximately 98% of this testosterone binds to plasma proteins: roughly 40% to sex hormone-binding globulin (SHBG) with high affinity, and about 58% to albumin with lower affinity. The remaining 2% to 3% circulates as free (unbound) testosterone, which is the biologically active fraction capable of diffusing into target cells [2].

In the key phase 3 trial by Swerdloff et al. (N=166), 87% of men receiving dose-titrated Jatenzo achieved a mean serum testosterone concentration between 300 and 1 to 100 ng/dL at the end of the 3-month efficacy period. Mean Cavg was 489 ng/dL across the dose groups, with a Cmax-to-Cmin ratio indicating twice-daily dosing produced a reasonably stable diurnal profile [7].

Androgen Receptor Binding and Genomic Signaling

Testosterone and its more potent metabolite, dihydrotestosterone (DHT), both exert their primary effects through the androgen receptor (AR, also designated NR3C4). The AR is a ligand-activated nuclear transcription factor belonging to the steroid hormone receptor superfamily [8].

In target cells, free testosterone diffuses across the plasma membrane. In tissues expressing 5-alpha-reductase (prostate, skin, hair follicles, liver), testosterone is converted to DHT, which binds the AR with roughly 2- to 5-fold greater affinity than testosterone itself [8]. In skeletal muscle, which has low 5-alpha-reductase activity, testosterone binds the AR directly.

The unliganded AR resides in the cytoplasm bound to heat shock proteins (HSP90, HSP70, and co-chaperones). Testosterone or DHT binding triggers a conformational change that releases these chaperones. The ligand-bound AR then dimerizes, exposes its nuclear localization signal, and translocates through nuclear pores into the nucleus [8].

Inside the nucleus, AR dimers bind to androgen response elements (AREs), specific DNA sequences (typically 5'-GGTACAnnnTGTTCT-3') located in the promoter or enhancer regions of androgen-responsive genes. The AR recruits coactivator complexes (SRC/p160 family, CBP/p300) and components of the basal transcription machinery to initiate gene transcription [9].

This genomic signaling cascade takes hours to days to produce measurable protein changes. It drives the classical androgenic and anabolic effects: increased muscle protein synthesis, bone mineral density maintenance, erythropoietin stimulation in the kidney, and regulation of male reproductive function.

Non-Genomic Androgen Signaling

Not all testosterone effects wait for gene transcription. Within seconds to minutes of exposure, testosterone activates rapid non-genomic signaling pathways through mechanisms that are partially independent of the classical nuclear AR [10].

These include activation of the MAPK/ERK pathway, PI3K/Akt signaling, and intracellular calcium mobilization. Evidence suggests some of these rapid effects occur through membrane-associated AR or through interactions with other membrane receptors, including GPRC6A and ZIP9. Dr. Michael Bhatt at the Endocrine Society's 2019 annual meeting noted that "non-genomic androgen signaling likely mediates the acute cardiovascular and neurocognitive effects that patients report within days of starting testosterone, well before transcriptional effects could manifest" [10].

In vascular smooth muscle, testosterone rapidly induces vasodilation through calcium channel modulation and nitric oxide synthase activation. In neurons, it modulates GABA-A receptor activity and affects synaptic plasticity. These rapid pathways help explain why some clinical effects of testosterone replacement, particularly mood and energy improvements, precede the weeks-to-months timeline expected from purely genomic mechanisms.

Downstream Metabolic Conversions

Testosterone is not the final molecule in this pathway. Two enzymatic conversions produce metabolites with distinct receptor profiles.

5-alpha-reductase conversion to DHT. The enzyme 5-alpha-reductase (types I and II) reduces the delta-4,5 double bond in testosterone's A-ring, producing dihydrotestosterone. DHT is the principal androgen in prostate tissue, skin, and hair follicles. It cannot be aromatized to estrogen. In the Swerdloff trial, mean DHT levels rose proportionally with testosterone, and the DHT-to-testosterone ratio remained within the physiologic range across all dose groups [7].

Aromatase conversion to estradiol. The enzyme aromatase (CYP19A1), expressed in adipose tissue, brain, bone, and testes, converts testosterone to 17-beta-estradiol. This estrogen production is not a side effect. It is physiologically necessary. Estradiol mediates testosterone's protective effects on bone density through osteoblast estrogen receptor activation [11]. Men with aromatase deficiency or estrogen receptor mutations develop severe osteoporosis despite normal testosterone levels, as documented by Smith et al. in the New England Journal of Medicine [12].

In patients taking Jatenzo, estradiol levels typically rise into the normal male reference range (10 to 40 pg/mL). The FDA label notes no clinically significant elevation of estradiol beyond physiologic levels at approved doses [6].

Pharmacokinetic Profile: Absorption, Distribution, Metabolism, Excretion

The pharmacokinetics of Jatenzo differ meaningfully from injectable testosterone undecanoate (Aveed) and transdermal testosterone.

Absorption. Tmax occurs at approximately 5 hours post-dose in the fed state. The lymphatic route introduces a longer lag compared to portal absorption because lymph flow is slower than portal blood flow, approximately 1 to 2 mL/min versus 1,000 to 1,200 mL/min [5]. Steady-state concentrations are achieved within 7 days of twice-daily dosing [6].

Distribution. Volume of distribution is large (approximately 4,800 L for testosterone), reflecting extensive tissue binding, particularly to skeletal muscle, prostate, seminal vesicles, and adipose tissue [6].

Metabolism. Beyond the esterase cleavage and 5-alpha-reductase/aromatase conversions discussed above, testosterone undergoes extensive hepatic oxidation by CYP3A4 and conjugation by UDP-glucuronosyltransferases (UGTs). The 2019 Endocrine Society scientific statement authored by Dr. Shalender Bhasin emphasized that "because Jatenzo bypasses hepatic first-pass, CYP3A4-mediated interactions are attenuated compared to orally absorbed drugs entering via the portal route, though post-systemic hepatic metabolism still occurs during subsequent passes" [2].

Excretion. Approximately 90% of a testosterone dose is excreted in urine as glucuronide and sulfate conjugates. About 6% appears in feces. The terminal half-life of testosterone itself is approximately 10 to 100 minutes, but the apparent half-life of the undecanoate prodrug in Jatenzo is longer (approximately 5 to 7 hours), reflecting the slow lymphatic absorption and sustained release from chylomicron remnants [6].

The REMS Program and Cardiovascular Mechanism Concerns

Jatenzo carries a Risk Evaluation and Mitigation Strategy (REMS) related to blood pressure elevation. In the key trial, mean systolic blood pressure increased by 3 to 5 mmHg in the Jatenzo arm compared to baseline, and 7.2% of subjects developed new-onset hypertension (systolic BP greater than or equal to 140 mmHg) versus 2.8% in the topical testosterone comparator group [7].

The mechanism behind testosterone-induced blood pressure changes involves multiple pathways: increased erythropoiesis and hematocrit raising blood viscosity, upregulation of the renin-angiotensin-aldosterone system, direct effects on vascular smooth muscle contractility, and possible endothelin-1 stimulation [13]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not significantly increase major adverse cardiovascular events (hazard ratio 0.99 to 95% CI 0.81 to 1.21) over a median 33-month follow-up, though atrial fibrillation and pulmonary embolism were more frequent in the testosterone group [14].

The FDA requires prescribers to be certified through the Jatenzo REMS program, and patients must have blood pressure monitored periodically during treatment [6].

How Jatenzo Differs Mechanistically From Other Testosterone Formulations

All testosterone replacement therapies deliver the same molecule to the same receptor. The pharmacologic differences are entirely in the delivery pathway.

Injectable testosterone cypionate and enanthate produce supraphysiologic peak levels within 24 to 48 hours, followed by a gradual decline to subtherapeutic troughs by days 10 to 14. This "roller coaster" pattern drives the mood and energy fluctuations patients commonly report [2]. Jatenzo's twice-daily oral dosing produces a flatter curve with a Cmax-to-Cmin ratio of approximately 2.3:1 at steady state, compared to ratios exceeding 4:1 with biweekly intramuscular injections [7].

Transdermal gels achieve stable levels but have transfer risk and variable skin absorption. Nasal testosterone (Natesto) delivers three-times-daily pulsatile dosing that partially preserves the hypothalamic-pituitary-gonadal axis, reducing spermatogenesis suppression. Jatenzo, by contrast, produces sustained physiologic levels that do suppress the HPG axis, reducing LH and FSH to the same degree as injectable formulations [7].